Stromal Signals Dominate Gene Expression Signature Scores That Aim to Describe Cancer Cell–intrinsic Stemness or Mesenchymality Characteristics
Open Access
- 23 February 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 4 (2) , 516-529
Abstract
Epithelial-to-mesenchymal transition (EMT) in cancer cells confers migratory abilities, a crucial aspect in the metastasis of tumors that frequently leads to death. In multiple studies, authors proposed gene expression signatures for EMT, stemness, or mesenchymality of tumors based on bulk tumor expression profiling. However, recent studies suggested that noncancerous cells from the microenvironment or macroenvironment heavily influence such signature profiles. Here, we strengthen these findings by investigating 11 published and frequently referenced gene expression signatures that were proposed to describe EMT-related (EMT, mesenchymal, or stemness) characteristics in various cancer types. By analyses of bulk, single-cell, and pseudobulk expression data, we show that the cell type composition of a tumor sample frequently dominates scores of these EMT-related signatures. A comprehensive, integrated analysis of bulk RNA sequencing (RNA-seq) and single-cell RNA-seq data shows that stromal cells, most often fibroblasts, are the main drivers of EMT-related signature scores. We call attention to the risk of false conclusions about tumor properties when interpreting EMT-related signatures, especially in a clinical setting: high patient scores of EMT-related signatures or calls of “stemness subtypes” often result from low cancer cell content in tumor biopsies rather than cancer cell–specific stemness or mesenchymal/EMT characteristics. Significance: Cancer self-renewal and migratory abilities are often characterized via gene module expression profiles, also called EMT or stemness gene expression signatures. Using published clinical tumor samples, cancer cell lines, and single cancer cells, we highlight the dominating influence of noncancer cells in low cancer cell content biopsies on their scores. We caution on their application for low cancer cell content clinical cancer samples with the intent to assign such characteristics or subtypes.Keywords
All Related Versions
Funding Information
- Merck | Merck Healthcare KGaA (10.13039/100009945)
- Merck | Merck Healthcare KGaA (10.13039/100009945)
This publication has 62 references indexed in Scilit:
- Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancerThe Journal of Pathology, 2013
- A colorectal cancer classification system that associates cellular phenotype and responses to therapyNature Medicine, 2013
- Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer GenesPLOS ONE, 2013
- Against quantiles: categorization of continuous variables in epidemiologic research, and its discontentsBMC Medical Research Methodology, 2012
- Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer OutcomePLOS Computational Biology, 2011
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypesProceedings of the National Academy of Sciences, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer PatientsCancer Research, 2005